Disease Activity Score and Disease Pathway Scores Measured Using the Multiple Sclerosis Disease Activity Test are Significantly Reduced Prior to the Week 96 Dose for Patients Treated with Ublituximab in the Phase 3 ULTIMATE I and II Studies

Download

site-sidebar-layout : default

ast-site-content-layout : default

site-content-style : default

site-sidebar-style : default

theme-transparent-header-meta : default

stick-header-meta : default

Drug Category : Array

Conference Category : Array

Lead Author : Foley J, et al.

Published Date : 12/10/2023

Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2023/10/Foley-MSMilan-2023-Disease-Activity-Score-and-Disease-Pathway.pdf

Download Text :

Popup Confirmation? :

astra-migrate-meta-layouts : set